IMDX Stock Analysis: Buy, Sell, or Hold?
IMDX - Insight Molecular Diagnostics Inc. Common Stock
$5.74
0.05 (0.88%)
▲
5d:
+2.68%
30d:
-3.53%
90d:
+66.86%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When IMDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IMDX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: IMDX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: IMDX is currently trading at $5.74, which is considered fair relative to its 30-day fair value range of $5.37 to $6.16.
Technical Outlook: Technically, IMDX is in a downtrend. Immediate support is located at $5.20, while resistance sits at $6.85.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.33 (+45.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMDX is in a downtrend. Immediate support is located at $5.20, while resistance sits at $6.85.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.33 (+45.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.37 -
$6.16
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.2% below Wall St target ($8.33)
Trading Range Analysis
30-Day Trading Range
$5.37 -
$6.16
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.03
(17.9%)
Support & Resistance Levels
Support Level
$5.20
Resistance Level
$6.85
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.36
Wall Street Target
$8.33
(+45.2%)
Revenue Growth (YoY)
-98.5%
Share & Embed Analysis
Last updated: July 02, 2026 10:34 PM ET
Data refreshes hourly during market hours. Next update: 11:34 PM
Data refreshes hourly during market hours. Next update: 11:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMDX showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Broadwood Partners, L.P.
BUY
40690 shares
2026-04-20
Broadwood Partners, L.P.
BUY
40114 shares
2026-04-17
Broadwood Partners, L.P.
BUY
102057 shares
2026-04-16
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$599 | 64 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 64 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$144 | 61 BUY |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$260 | 54 HOLD |